Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) FCF Margin (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed FCF Margin for 6 consecutive years, with 790.61% as the latest value for Q2 2025.

  • On a quarterly basis, FCF Margin changed N/A to 790.61% in Q2 2025 year-over-year; TTM through Dec 2025 was 3706.93%, a 472227.0% decrease, with the full-year FY2025 number at 3666.65%, down 584577.0% from a year prior.
  • FCF Margin was 790.61% for Q2 2025 at Outlook Therapeutics, down from 1116.62% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 790.61% in Q2 2025 to a low of 790.61% in Q2 2025.